Csenge Advisory Group Biogen Inc. Transaction History

Csenge Advisory Group

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 21, 2021	SELL	$259.0 - $414.71 $266,252 - $426,321	-1,028 Closed	0 $0
Q1 2021 Apr 28, 2021	SELL	$242.95 - $284.63 $56,607 - $66,318	-233 Reduced 18.48%	1,028 $276,000
Q4 2020 Jan 26, 2021	SELL	$236.26 - $355.63 $1,417 - $2,133	-6 Reduced 0.47%	1,261 $309,000
Q3 2020 Nov 09, 2020	BUY	$264.77 - $305.71 $20,122 - $23,233	76 Added 6.38%	1,267 $356,000
Q2 2020 Jul 17, 2020	BUY	$258.66 - $342.55 $308,064 - $407,977	1,191 New	1,191 $319,000

Q4 2018 Feb 07, 2019	SELL	$278.5 - $352.75 $84,942 - $107,588	-305 Closed	0 $0
Q3 2018 Nov 19, 2018	BUY	$293.51 - $383.83 $89,520 - $117,068	305 New	305 $95,000
Q2 2018 Aug 10, 2018	SELL	$257.52 - $306.91 $192,882 - $229,875	-749 Closed	0 $0
Q1 2018 May 10, 2018	BUY	$260.13 - $367.91 $780 - $1,103	3 Added 0.4%	749 $205,000
Q4 2017 Feb 15, 2018	BUY	$307.64 - $344.58 $229,499 - $257,056	746	746 $238,000

1,046

126M

1.37M

1.35M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Csenge Advisory Group, based on Form 13F filings with the SEC.

Stay updated on Csenge Advisory Group with notifications on news.